MCID: GLB007
MIFTS: 29

Glioblastoma 3

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Glioblastoma 3

MalaCards integrated aliases for Glioblastoma 3:

Name: Glioblastoma 3 54 13
Glioma Susceptibility 3 29
Glioma 3 71
Glm3 71

Characteristics:

OMIM:

54
Inheritance:
autosomal recessive


Classifications:



External Ids:

OMIM 54 613029
MedGen 40 C2751641
MeSH 42 D005910
SNOMED-CT via HPO 65 443333004 83217000 63634009

Summaries for Glioblastoma 3

UniProtKB/Swiss-Prot : 71 Glioma 3: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

MalaCards based summary : Glioblastoma 3, is also known as glioma susceptibility 3, and has symptoms including medulloblastoma and glioblastoma. An important gene associated with Glioblastoma 3 is BRCA2 (BRCA2, DNA Repair Associated). The drugs Irinotecan and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and prostate.

Description from OMIM: 613029

Related Diseases for Glioblastoma 3

Diseases in the Glioblastoma family:

Glioblastoma 3

Symptoms & Phenotypes for Glioblastoma 3

Symptoms via clinical synopsis from OMIM:

54

Neoplasia:
astrocytoma
medulloblastoma
glioblastoma
brain tumors, multiple types


Clinical features from OMIM:

613029

Human phenotypes related to Glioblastoma 3:

32
id Description HPO Frequency HPO Source Accession
1 medulloblastoma 32 HP:0002885
2 glioblastoma 32 HP:0100843

Drugs & Therapeutics for Glioblastoma 3

Drugs for Glioblastoma 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 418)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
2
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
3
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
4
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
5
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
6
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
7 Thiotepa Approved Phase 2, Phase 3 52-24-4 5453
8
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
9
Procarbazine Approved Phase 3,Phase 2 671-16-9 4915
10
Trioxsalen Approved Phase 3 3902-71-4 5585
11
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
12
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
14
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1 341031-54-7, 557795-19-4 5329102
15
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
16
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
17
chloroquine Approved, Vet_approved Phase 3,Phase 1 54-05-7 2719
18
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
19
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
22
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
23
Morphine Approved, Investigational Phase 3 57-27-2 5288826
24
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
25
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
26
Flucytosine Approved Phase 2, Phase 3,Phase 1 2022-85-7 3366
27
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
28
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
29
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
30
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
31
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
32
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
33
Copper Approved Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
34
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
35
Losartan Approved Phase 3 114798-26-4 3961
36
Dopamine Approved Phase 3,Phase 1 51-61-6, 62-31-7 681
37
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
38
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
39
Norepinephrine Approved Phase 3 51-41-2 439260
40
Cyproheptadine Approved Phase 3 129-03-3 2913
41
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
42 tannic acid Approved, Nutraceutical Phase 3,Phase 2
43
Vitamin C Approved, Nutraceutical Phase 3,Phase 1 50-81-7 5785 54670067
44
Camptothecin Experimental Phase 2, Phase 3,Phase 1 7689-03-4
45
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
46 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
47
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
48 Dianhydrogalactitol Investigational Phase 3,Phase 2 23261-20-3
49
Angiotensin II Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
50 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1

Interventional clinical trials:

(show top 50) (show all 507)

id Name Status NCT ID Phase Drugs
1 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
2 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
4 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
5 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
6 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
7 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
8 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
9 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
10 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
11 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
12 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
13 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
14 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
15 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
16 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
17 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
18 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
19 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
20 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
21 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
22 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
23 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
24 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
25 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3 TransMID
26 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
27 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
28 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
29 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
30 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
31 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
32 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
33 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
34 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
35 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
36 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
37 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Recruiting NCT01507506 Phase 3
38 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Recruiting NCT02667587 Phase 3 Nivolumab;Temozolomide
39 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Recruiting NCT02617589 Phase 3 Nivolumab;Temozolomide
40 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Recruiting NCT02761070 Phase 3 Temozolomide;Bevacizumab
41 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) Recruiting NCT03291977 Phase 3 Fluorescéine Sodique Faure
42 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3 Temozolomide
43 Disulfiram in Recurrent Glioblastoma Recruiting NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
44 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
45 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
46 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
47 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Active, not recruiting NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
48 P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA Active, not recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
49 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Active, not recruiting NCT02017717 Phase 3
50 Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Active, not recruiting NCT00884741 Phase 3 Placebo;Temozolomide pre-randomization;Temozolomide post-randomization

Search NIH Clinical Center for Glioblastoma 3

Genetic Tests for Glioblastoma 3

Genetic tests related to Glioblastoma 3:

id Genetic test Affiliating Genes
1 Glioma Susceptibility 3 29

Anatomical Context for Glioblastoma 3

MalaCards organs/tissues related to Glioblastoma 3:

39
Brain, T Cells, Prostate, Liver, Bone, Colon, Endothelial

Publications for Glioblastoma 3

Variations for Glioblastoma 3

ClinVar genetic disease variations for Glioblastoma 3:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
2 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh37 Chromosome 13, 32914137: 32914137

Expression for Glioblastoma 3

Search GEO for disease gene expression data for Glioblastoma 3.

Pathways for Glioblastoma 3

GO Terms for Glioblastoma 3

Sources for Glioblastoma 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....